Neuropathologic Changes of Multiple System Atrophy and Diffuse Lewy Body Disease

 

 Buy Article Permissions and Reprints

Abstract

The accumulation of fibrillar α-synuclein protein is the pathological hallmark occurring in both multiple system atrophy (MSA) and diffuse Lewy body disease (DLBD). The oligodendrocytes are especially involved in MSA, while subtypes of neurons are the targets in DLBD. In both instances, the changes are widespread within the central nervous system, but with distinct and topistic vulnerability.

Two diagnostic subtypes of MSA are currently applied: multiple system atrophy-cerebellar (MSA-C), formerly designated olivopontocerebellar atrophy, and multiple system atrophy-parkinsonian (MSA-P), formerly called striatonigral degeneration. However, overlaps exist between them, notably during the late stages of the illness. The brainstem and cerebellum are especially vulnerable and dysfunctional in MSA-C, but the striatum and mesencephalon in MSA-P, wherein parkinsonism usually prevails.

In DLBD, Lewy-body-containing neurons (LBCN) involve the cerebral cortex in addition to the sites affected in Parkinson disease (PD). Thus, dementia and parkinsonism occur, often without brain atrophy. Then, two main pathological subtypes are used: the limbic or the cortical type. Possibly, DLBD, either the limbic or cortical-type, is the ultimate stage of PD, which corresponds to the brainstem type.

The epidemiologic and genetic traits causing sporadic MSA and sporadic DLBD are not known.

• References

• 1 Vonsattel JPG, Del Amaya MP, Keller CE. Twenty-first century brain banking. Processing brains for research: the Columbia University methods. Acta Neuropathol 2008; 115 (5) 509-532
  CrossrefPubMedGoogle Scholar
• 2 Mirra SS, Heyman A, McKeel D , et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41 (4) 479-486
  CrossrefPubMedGoogle Scholar
• 3 Hyman BT, Phelps CH, Beach TG , et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8 (1) 1-13
  CrossrefPubMedGoogle Scholar
• 4 Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112 (4) 389-404
  CrossrefPubMedGoogle Scholar
• 5 The National Institute on Aging; Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging 1997; 18 (4, Suppl) S1-S2
  CrossrefPubMedGoogle Scholar
• 6 Trojanowski JQ, Revesz T . Neuropathology Working Group on MSA. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 2007; 33 (6) 615-620
  CrossrefPubMedGoogle Scholar
• 7 McKeith IG, Dickson DW, Lowe J , et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65 (12) 1863-1872
  CrossrefPubMedGoogle Scholar
• 8 Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24 (2) 197-211
  CrossrefPubMedGoogle Scholar
• 9 Papp MI, Lantos PL. Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy. J Neurol Sci 1992; 107 (2) 172-182
  CrossrefPubMedGoogle Scholar
• 10 Lantos PL, Papp MI. Cellular pathology of multiple system atrophy: a review. J Neurol Neurosurg Psychiatry 1994; 57 (2) 129-133
  CrossrefPubMedGoogle Scholar
• 11 Dickson DW, Liu W, Hardy J , et al. Widespread alterations of α-synuclein in multiple system atrophy. Am J Pathol 1999; 155 (4) 1241-1251
  CrossrefPubMedGoogle Scholar
• 12 Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997; 12 (2) 133-147
  CrossrefPubMedGoogle Scholar
• 13 Poston KL, Tang CC, Eckert T , et al. Network correlates of disease severity in multiple system atrophy. Neurology 2012; 78 (16) 1237-1244
  CrossrefPubMedGoogle Scholar
• 14 Iodice V, Lipp A, Ahlskog JE , et al. Autopsy confirmed multiple system atrophy cases: Mayo experience and role of autonomic function tests. J Neurol Neurosurg Psychiatry 2012; 83 (4) 453-459
  CrossrefPubMedGoogle Scholar
• 15 Gilman S, Wenning GK, Low PA , et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71 (9) 670-676
  CrossrefPubMedGoogle Scholar
• 16 Jellinger KA, Seppi K, Wenning GK. Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord 2005; 20 (Suppl. 12) S29-S36
  CrossrefPubMedGoogle Scholar
• 17 Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG. Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol 2008; 64 (3) 239-246
  CrossrefPubMedGoogle Scholar
• 18 Duda JE, Giasson BI, Gur TL , et al. Immunohistochemical and biochemical studies demonstrate a distinct profile of α-synuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol 2000; 59 (9) 830-841
  PubMedGoogle Scholar
• 19 Armstrong RA, Cairns NJ, Lantos PL. Multiple system atrophy (MSA): topographic distribution of the α-synuclein-associated pathological changes. Parkinsonism Relat Disord 2006; 12 (6) 356-362
  CrossrefPubMedGoogle Scholar
• 20 Nirenberg MJ, Libien J, Vonsattel J-P, Fahn S. Multiple system atrophy in a patient with the spinocerebellar ataxia 3 gene mutation. Mov Disord 2007; 22 (2) 251-254
  CrossrefPubMedGoogle Scholar
• 21 Yoshizawa H, Vonsattel JP, Honig LS. Early neuropsychological discriminants for Lewy body disease: an autopsy series. J Neurol Neurosurg Psychiatry 2013; 84 (12) 1326-1330
  CrossrefPubMedGoogle Scholar
• 22 Johnson DK, Morris JC, Galvin JE. Verbal and visuospatial deficits in dementia with Lewy bodies. Neurology 2005; 65 (8) 1232-1238
  CrossrefPubMedGoogle Scholar
• 23 Litvan I, MacIntyre A, Goetz CG , et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 1998; 55 (7) 969-978
  CrossrefPubMedGoogle Scholar
• 24 Brown DF, Dababo MA, Bigio EH , et al. Neuropathologic evidence that the Lewy body variant of Alzheimer disease represents coexistence of Alzheimer disease and idiopathic Parkinson disease. J Neuropathol Exp Neurol 1998; 57 (1) 39-46
  CrossrefPubMedGoogle Scholar
• 25 Jellinger KA. Lewy body-related α-synucleinopathy in the aged human brain. J Neural Transm 2004; 111 (10-11) 1219-1235
  CrossrefPubMedGoogle Scholar
• 26 Lippa CF, Duda JE, Grossman M , et al; DLB/PDD Working Group. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68 (11) 812-819
  CrossrefPubMedGoogle Scholar
• 27 McKeith I, Mintzer J, Aarsland C , et al. Dementia with Lewy bodies. Lancet Neurol 2004; 3: 19-28
  CrossrefPubMedGoogle Scholar
• 28 Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996; 55 (3) 259-272
  CrossrefPubMedGoogle Scholar
• 29 Gómez-Tortosa E, Irizarry MC, Gómez-Isla T, Hyman BT. Clinical and neuropathological correlates of dementia with Lewy bodies. Ann N Y Acad Sci 2000; 920: 9-15
  PubMedGoogle Scholar
• 30 Kosaka K, Iseki E. Clinicopathological studies on diffuse Lewy body disease. Neuropathology 2000; 20 (1) 1-7
  PubMedGoogle Scholar
• 31 Gómez-Isla T, Growdon WB, McNamara M , et al. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 1999; 53 (9) 2003-2009
  CrossrefPubMedGoogle Scholar
• 32 Del Tredici K, Rüb U, De Vos RAI, Bohl JRE, Braak H. Where does parkinson disease pathology begin in the brain?. J Neuropathol Exp Neurol 2002; 61 (5) 413-426
  CrossrefPubMedGoogle Scholar
• 33 Dickson DW, Ruan D, Crystal H , et al. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology 1991; 41 (9) 1402-1409
  CrossrefPubMedGoogle Scholar
• 34 Hansen L, Salmon D, Galasko D , et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990; 40 (1) 1-8
  PubMedGoogle Scholar
• 35 Clark LN, Kartsaklis LA, Wolf Gilbert R , et al. Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol 2009; 66 (5) 578-583
  CrossrefPubMedGoogle Scholar
• 36 Sharp ME, Marder KS, Cote L , et al. Parkinson's disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation. Mov Disord 2014; 29 (4) 566-568
  CrossrefPubMedGoogle Scholar
• 37 Poulopoulos M, Cortes E, Vonsattel J-PG , et al. Clinical and pathological characteristics of LRRK2 G2019S patients with PD. J Mol Neurosci 2012; 47 (1) 139-143
  CrossrefPubMedGoogle Scholar